Blueprint Medicines' increased debt brings a heightened risk...
Blueprint Medicines' increased debt brings a heightened risk profile due to last year's dilution in revenues and lack of profitability. Its future earnings and balance sheet health are key to assessing risk.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000165248ed181335.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment